Loading the security overview…
Where the tokens are
Peers
11 of 14 have tokenized versionsFirst the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside BRKR. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
 BRKRThis companyBruker Corporation | — | $9.44B | — | 2.7 | 25.7 | −4.5% | 4/9 | safe |
 TMOTokenizedThermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $241.26B | 34.6 | 5.2 | 24.6 | 13.2% | 6/9 | safe |
 HWMTokenizedHowmet Aerospace Inc. | Advanced Instruments & Research Tools | $91.08B | 48.6 | 10.0 | 34.0 | 32.7% | 8/9 | safe |
 ATokenizedAgilent Technologies Inc. | Clinical-Stage Platforms | $46.99B | 32.6 | 6.4 | 25.8 | 19.6% | 6/9 | safe |
 IQVTokenizedIQVIA Holdings Inc. | Clinical-Stage Platforms | $42.91B | 31.2 | 2.5 | 16.1 | 22.3% | 5/9 | grey |
 WATTokenizedWaters Corp | Clinical-Stage Platforms | $41.81B | 251.6 | 9.0 | 83.5 | 1.1% | 5/9 | safe |
 WSTTokenizedWest Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $25.69B | 45.5 | 7.7 | 28.2 | 18.9% | 7/9 | safe |
 RPRXRoyalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.66B | 31.5 | 10.1 | 19.8 | 11.9% | 6/9 | safe |
 ASNDTokenizedAscendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $17.53B | — | — | — | — | 2/9 | — |
 MEDPTokenizedMedpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.69B | 34.0 | 6.0 | 26.5 | 113.3% | 6/9 | safe |
 RVTYTokenizedRevvity, Inc. | Clinical-Stage Platforms | $16.63B | 70.0 | 5.7 | 24.4 | 3.3% | 7/9 | safe |
 CRLCharles River Laboratories International, Inc. | Clinical-Stage Platforms | $13.69B | — | 3.4 | 21.1 | −8.4% | 6/9 | safe |
 ICLRIcon Plc | Clinical-Stage Platforms | $12.49B | 37.0 | 4.3 | 25.3 | 17.5% | 7/9 | grey |
 TWSTTokenizedTwist Bioscience Corporation Common Stock | Clinical-Stage Platforms | $12.47B | — | 28.9 | -110.0 | −30.7% | 3/9 | safe |
 HALOTokenizedHalozyme Therapeutics, Inc. | Clinical-Stage Platforms | $12.14B | 29.4 | 7.3 | 13.5 | 288.1% | 6/9 | safe |
Figures describe Bruker shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.